This excerpt taken from the EYE 8-K filed Feb 14, 2006.
Ophthalmic Surgical Sales
Ophthalmic surgical revenue grew 49.9 percent in 2005 to $619.8 million. There was virtually no impact related to foreign currency for the full year. In the fourth quarter of 2005, sales were $186.5 million, up 38.1 percent, including a 5.1 percent decrease related to foreign currency. The annual and fourth-quarter growth illustrated the impacts of recent acquisitions, increased sales of technologically advanced products and declining sales of non-strategic products being discontinued. Below are highlights of AMOs ophthalmic surgical product categories. Growth rates reflect comparisons to the same periods in 2004 and include the impacts of foreign currency.
For the year, total cataract/implant sales rose 23 percent to $496.4 million, reflecting the full year contribution of the 2004 Pfizer acquisition and increased sales of value-added technologically advanced products. In the fourth quarter, sales growth related to these advanced products was partially offset by the accelerated phase-out of older-generation products and a negative currency effect, resulting in a 0.02 percent sales decline to $132.3 million.
Total IOL sales grew 10 percent to $259.1 million in 2005. Fourth-quarter sales rose 1.5 percent to $69.4 million. This performance was attributed primarily to increased sales of Tecnis® and other premium IOLs, as well as the accelerated phase-out of older-generation silicone and PMMA (polymethyl methacrylate) IOLs. Together, the companys refractive IOLs Tecnis® Multifocal, ReZoomTM and VerisyseTM contributed $22.9 million to total 2005 IOL sales.
Viscoelastics sales grew 76.6 percent in 2005 to $131.2 million, reflecting primarily the addition of the Healon® line, which the company acquired with the Pfizer transaction.
Fourth-quarter viscoelastics sales declined 9.9 percent to $33.5 million, as Healon® sales performance was masked by declining sales of discontinued viscoelastics, reimbursement pressures in certain international markets and unfavorable foreign currency translations.
Phacoemulsification sales rose 7.5 percent in 2005 to $80.8 million. Fourth-quarter sales were up 7.9 percent to $22.5 million. Strong sales of AMOs proprietary Sovereign® systems with WhiteStar® technology, as well as the surgical packs and accessories that support these systems, led this growth.
Laser Vision Correction (LVC):
LVC sales were $123.4 million in 2005. Fourth-quarter LVC sales were $54.2, up 26 percent versus the combined VISX LVC and AMO microkeratome sales in the year-ago period. The increase reflects growth in the U.S. LVC business, increased sales related to the companys international expansion and strong microkeratome sales.
LVC licensing and related sales for 2005 totaled $70.8 million. Fourth-quarter sales of $29.9 million reflected an approximate 10 percent increase over VISXs reported licensing and related sales in the same period last year. The improvement is attributed to an increase in the mix of CustomVue® LASIK procedures.
LVC system sales in 2005 were $27.1 million. Fourth-quarter sales of $14.2 million represented an approximate 79 percent increase compared to VISXs reported system sales in the same period last year. The rise is due primarily to the increase in new unit placements and CustomVue® upgrades in targeted international markets, as well as the continued rollout of Iris Registration in the U.S. LVC service and parts sales in 2005 were $13.2 million, including $5.9 million in the fourth quarter. The fourth-quarter performance reflected an increase of approximately 13 percent compared to VISXs reported service and parts sales in the same period last year.
This excerpt taken from the EYE 8-K filed Nov 2, 2005.
Ophthalmic Surgical Sales
Ophthalmic surgical sales grew 50.4 percent in the quarter to $170.6 million, including a 0.3 percent positive impact related to foreign currency. Sales related to the VISX acquisition of $47.7 million accounted for 42.0 percent of the growth. Quarterly ophthalmic surgical sales highlights are provided below. Growth rates reflect comparisons to the same period in 2004.
Laser Vision Correction: